FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
A new perspective from the U.S. FDA...
26 March 2013 | By Boehringer Ingelheim
A new perspective from the U.S. FDA...
List view / Grid view
Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.
A new perspective from the U.S. FDA...
26 March 2013 | By Boehringer Ingelheim
A new perspective from the U.S. FDA...
Boehringer Ingelheim and Eli Lilly and Company announced today the…
19 March 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…
International peer-to-peer sharing...
11 March 2013 | By Boehringer Ingelheim
International peer-to-peer sharing...
Interim study results from STARTversoTM 4...
4 March 2013 | By Boehringer Ingelheim
Interim study results from STARTversoTM 4...
New Phase III data presented...
23 February 2013 | By Boehringer Ingelheim
New Phase III data presented...
Olodaterol may provide a new treatment option in patients with…
29 January 2013 | By Boehringer Ingelheim
Olodaterol may provide a new treatment option in patients with COPD...
Submissions opened for diabetes research grant applications from across Europe...
17 January 2013 | By Boehringer Ingelheim
Submissions opened for diabetes research grant applications from across Europe...
"Diabetes affects more than 371m people..."
17 January 2013 | By Boehringer Ingelheim
"Diabetes affects more than 371m people..."
The acceptance of the NDA filing reinforces our ongoing commitment…
16 January 2013 | By Boehringer Ingelheim
The acceptance of the NDA filing reinforces our ongoing commitment to oncology..."
Top-line results for four completed Phase III clinical trials...
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
Results from a new post-hoc analysis...
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...
New positive Phase II results...
10 December 2012 | By Boehringer Ingelheim
New positive Phase II results...
Pivotal Phase III interferon-free study being initiated following positive Phase…
10 November 2012 | By Boehringer Ingelheim
Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...
Pivotal data from the RELY-ABLE® study have provided additional data...
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
Boehringer Ingelheim and Eli Lilly and Company are pleased to…
8 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in…